These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25682700)

  • 21. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
    Sun F; Tai S; Lim T; Baumann U; King M
    Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro.
    Rubin BK; Kater AP; Goldstein AL
    Chest; 2006 Nov; 130(5):1433-40. PubMed ID: 17099021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
    Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
    Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.
    Mendelman PM; Smith AL; Levy J; Weber A; Ramsey B; Davis RL
    Am Rev Respir Dis; 1985 Oct; 132(4):761-5. PubMed ID: 3931522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elastic contributions dominate the viscoelastic properties of sputum from cystic fibrosis patients.
    Nielsen H; Hvidt S; Sheils CA; Janmey PA
    Biophys Chem; 2004 Dec; 112(2-3):193-200. PubMed ID: 15572248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of a bacterial alginate lyase to purulent CF sputum in vitro can result in the disruption of alginate and modification of sputum viscoelasticity.
    Mrsny RJ; Lazazzera BA; Daugherty AL; Schiller NL; Patapoff TW
    Pulm Pharmacol; 1994 Dec; 7(6):357-66. PubMed ID: 7549223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies.
    Mrsny RJ; Daugherty AL; Short SM; Widmer R; Siegel MW; Keller GA
    J Drug Target; 1996; 4(4):233-43. PubMed ID: 9010813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
    Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
    Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis and bacterial colonization define the sputum N-glycosylation phenotype.
    Venkatakrishnan V; Thaysen-Andersen M; Chen SC; Nevalainen H; Packer NH
    Glycobiology; 2015 Jan; 25(1):88-100. PubMed ID: 25190359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum.
    Schiller NL; Millard RL
    Pediatr Res; 1983 Sep; 17(9):747-52. PubMed ID: 6413945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
    Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR; Pressler T; Koch C; Høiby N
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
    Sanderson K; Wescombe L; Kirov SM; Champion A; Reid DW
    Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
    Yang Y; Tsifansky MD; Wu CJ; Yang HI; Schmidt G; Yeo Y
    Pharm Res; 2010 Jan; 27(1):151-60. PubMed ID: 19847626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.
    Cheng K; Smyth RL; Govan JR; Doherty C; Winstanley C; Denning N; Heaf DP; van Saene H; Hart CA
    Lancet; 1996 Sep; 348(9028):639-42. PubMed ID: 8782753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
    Emerson J; McNamara S; Buccat AM; Worrell K; Burns JL
    Pediatr Pulmonol; 2010 Apr; 45(4):363-70. PubMed ID: 20232473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.